TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression
Antimicrobial Agents and Chemotherapy · 2025
DOI: 10.1128/aac.01508-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Tatsuro Hirayama und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan. Hauptthemen laut MEDLINE: Antifungal Agents, Fungal Proteins, Candida auris, Drug Resistance, Fungal. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MEXT | Japan Society for the Promotion of Science (JSPS), Japan Agency for Medical Research and Development (AMED), MSD Life Science Foundation, Public Interest Incorporated Foundation (SD Life Science Foundation).
Abstract (Originalsprache)
Candida auris is an emerging pathogenic fungus that is highly resistant to existing antifungal drugs. Manogepix is a novel antifungal agent that exerts antifungal activity by inhibiting glycosylphosphatidylinositol anchor biosynthesis. Although the mechanisms of resistance of Candida species to manogepix have been reported previously, those of C. auris are yet to be studied. To investigate the resistance mechanisms of C. auris , we exposed a clinical isolate (clade I) to manogepix in vitro and generated strains with reduced susceptibility to manogepix. A search for gain-of-function mutations that upregulate efflux pump expression confirmed the presence of the D865N amino acid mutation in TAC1b . We used the clustered regularly interspaced short palindromic repeats-Cas9 system to create a recovery strain (N865D) in which only this single nucleotide mutation was returned to the wild-type sequence. We generated a mutant strain by introducing only the D865N mutation into the parent strain and a different clade strain (clade III). The D865N mutant strains were clearly less susceptible to manogepix than the parental strains and exhibited high CDR1 expression. Moreover, we generated a strain deficient in CDR1 and confirmed that this strain had significantly increased susceptibility to manogepix. Thus, the present study demonstrated that the TAC1b mutation in C. auris upregulates CDR1 expression and decreases its susceptibility to manogepix.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacotherapeutics, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
- Division of Respirology, Rheumatology, Infectious Diseases, and Neurology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan.
- Infectious Diseases Experts Training Center, Nagasaki University Hospital, Nagasaki, Japan.
- Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.
- Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan.
ORCID-Profile: Tatsuro Hirayama, Masato Tashiro, Takahiro Takazono
Förderung
- MEXT | Japan Society for the Promotion of Science (JSPS)
- Japan Agency for Medical Research and Development (AMED)
- MSD Life Science Foundation, Public Interest Incorporated Foundation (SD Life Science Foundation)
Zitieren
APA
Hirayama, T., Miyazaki, T., Tanaka, R., Kitahori, N., Yoshida, M., Takeda, K., Ide, S., Iwanaga, N., Tashiro, M., Takazono, T., Izumikawa, K., Yanagihara, K., Makimura, K., Tsukamoto, K., & Mukae, H. (2025). TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01508-24
Vancouver
Hirayama T, Miyazaki T, Tanaka R, Kitahori N, Yoshida M, Takeda K, et al. TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.01508-24
BibTeX
@article{Hirayama2025,
author = {Hirayama, Tatsuro and Miyazaki, Taiga and Tanaka, Rina and Kitahori, Natsume and Yoshida, Masataka and Takeda, Kazuaki and Ide, Shotaro and Iwanaga, Naoki and Tashiro, Masato and Takazono, Takahiro and Izumikawa, Koichi and Yanagihara, Katsunori and Makimura, Koichi and Tsukamoto, Kazuhiro and Mukae, Hiroshi},
title = {TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2025},
doi = {10.1128/aac.01508-24}
}
EUVIMED